Jonas Alexander Gross-Isselmann, Torsten Eggert, Alina Wildenauer, Sarah Dietz-Terjung, Martina Grosse Sundrup, Christoph Schoebel
{"title":"将 Sleepiz One + 验证为非接触式诊断睡眠呼吸暂停的雷达传感器。","authors":"Jonas Alexander Gross-Isselmann, Torsten Eggert, Alina Wildenauer, Sarah Dietz-Terjung, Martina Grosse Sundrup, Christoph Schoebel","doi":"10.1007/s11325-024-03057-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The cardiorespiratory polysomnography (PSG) is an expensive and limited resource. The Sleepiz One + is a novel radar-based contactless monitoring device that can be used e.g. for longitudinal detection of nocturnal respiratory events. The present study aimed to compare the performance of the Sleepiz One + device to the PSG regarding the accuracy of apnea-hypopnea index (AHI).</p><p><strong>Methods: </strong>From January to December 2021, a total of 141 adult volunteers who were either suspected of having sleep apnea or who were healthy sleepers took part in a sleep study. This examination served to validate the Sleepiz One + device in the presence and absence of additional SpO2 information. The AHI determined by the Sleepiz One + monitor was estimated automatically and compared with the AHI derived from manual PSG scoring.</p><p><strong>Results: </strong>The correlation between the Sleepiz-AHI and the PSG-AHI with and without additional SpO2 measurement was r<sub>p</sub> = 0.94 and r<sub>p</sub> = 0,87, respectively. In general, the Bland-Altman plots showed good agreement between the two methods of AHI measurement, though their deviations became larger with increasing sleep-disordered breathing. Sensitivity and specificity for recordings without additional SpO2 was 85% and 88%, respectively. Adding a SpO2 sensor increased the sensitivity to 88% and the specificity to 98%.</p><p><strong>Conclusion: </strong>The Sleepiz One + device is a valid diagnostic tool for patients with moderate to severe OSA. It can also be easily used in the home environment and is therefore beneficial for e.g. immobile and infectious patients. TRIAL REGISTRATION NUMBER AND DATE OF REGISTRATION FOR PROSPECTIVELY REGISTERED TRIALS: This study was registered on clinicaltrials.gov (NCT04670848) on 2020-12-09.</p>","PeriodicalId":21862,"journal":{"name":"Sleep and Breathing","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11303430/pdf/","citationCount":"0","resultStr":"{\"title\":\"Validation of the Sleepiz One + as a radar-based sensor for contactless diagnosis of sleep apnea.\",\"authors\":\"Jonas Alexander Gross-Isselmann, Torsten Eggert, Alina Wildenauer, Sarah Dietz-Terjung, Martina Grosse Sundrup, Christoph Schoebel\",\"doi\":\"10.1007/s11325-024-03057-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>The cardiorespiratory polysomnography (PSG) is an expensive and limited resource. The Sleepiz One + is a novel radar-based contactless monitoring device that can be used e.g. for longitudinal detection of nocturnal respiratory events. The present study aimed to compare the performance of the Sleepiz One + device to the PSG regarding the accuracy of apnea-hypopnea index (AHI).</p><p><strong>Methods: </strong>From January to December 2021, a total of 141 adult volunteers who were either suspected of having sleep apnea or who were healthy sleepers took part in a sleep study. This examination served to validate the Sleepiz One + device in the presence and absence of additional SpO2 information. The AHI determined by the Sleepiz One + monitor was estimated automatically and compared with the AHI derived from manual PSG scoring.</p><p><strong>Results: </strong>The correlation between the Sleepiz-AHI and the PSG-AHI with and without additional SpO2 measurement was r<sub>p</sub> = 0.94 and r<sub>p</sub> = 0,87, respectively. In general, the Bland-Altman plots showed good agreement between the two methods of AHI measurement, though their deviations became larger with increasing sleep-disordered breathing. Sensitivity and specificity for recordings without additional SpO2 was 85% and 88%, respectively. Adding a SpO2 sensor increased the sensitivity to 88% and the specificity to 98%.</p><p><strong>Conclusion: </strong>The Sleepiz One + device is a valid diagnostic tool for patients with moderate to severe OSA. It can also be easily used in the home environment and is therefore beneficial for e.g. immobile and infectious patients. TRIAL REGISTRATION NUMBER AND DATE OF REGISTRATION FOR PROSPECTIVELY REGISTERED TRIALS: This study was registered on clinicaltrials.gov (NCT04670848) on 2020-12-09.</p>\",\"PeriodicalId\":21862,\"journal\":{\"name\":\"Sleep and Breathing\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2024-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11303430/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Sleep and Breathing\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s11325-024-03057-6\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/5/14 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sleep and Breathing","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11325-024-03057-6","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/14 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的：心肺多导睡眠图（PSG）是一种昂贵而有限的资源。Sleepiz One + 是一种基于雷达的新型非接触式监测设备，可用于纵向检测夜间呼吸事件等。本研究旨在比较 Sleepiz One + 设备与 PSG 在呼吸暂停-低通气指数（AHI）准确性方面的性能：从 2021 年 1 月到 12 月，共有 141 名疑似患有睡眠呼吸暂停或睡眠健康的成年志愿者参加了睡眠研究。这项检查的目的是验证 Sleepiz One + 设备在有或没有额外 SpO2 信息的情况下是否有效。Sleepiz One + 监测器自动估算出 AHI，并与人工 PSG 评分得出的 AHI 进行比较：结果：Sleepiz-AHI 与 PSG-AHI 在有和没有额外 SpO2 测量时的相关性分别为 rp = 0.94 和 rp = 0.87。总的来说，Bland-Altman 图显示两种 AHI 测量方法之间的一致性很好，但随着睡眠呼吸紊乱程度的增加，两者之间的偏差也越来越大。不添加 SpO2 的记录灵敏度和特异性分别为 85% 和 88%。添加 SpO2 传感器后，灵敏度提高到 88%，特异性提高到 98%：Sleepiz One + 设备是中重度 OSA 患者的有效诊断工具。结论：Sleepiz One + 设备是一种有效的诊断工具，适用于中度和重度 OSA 患者，也可在家庭环境中轻松使用，因此对行动不便和感染性患者等非常有益。前瞻性注册试验的注册号和注册日期：本研究于 2020-12-09 在 clinicaltrials.gov (NCT04670848) 上注册。
Validation of the Sleepiz One + as a radar-based sensor for contactless diagnosis of sleep apnea.
Purpose: The cardiorespiratory polysomnography (PSG) is an expensive and limited resource. The Sleepiz One + is a novel radar-based contactless monitoring device that can be used e.g. for longitudinal detection of nocturnal respiratory events. The present study aimed to compare the performance of the Sleepiz One + device to the PSG regarding the accuracy of apnea-hypopnea index (AHI).
Methods: From January to December 2021, a total of 141 adult volunteers who were either suspected of having sleep apnea or who were healthy sleepers took part in a sleep study. This examination served to validate the Sleepiz One + device in the presence and absence of additional SpO2 information. The AHI determined by the Sleepiz One + monitor was estimated automatically and compared with the AHI derived from manual PSG scoring.
Results: The correlation between the Sleepiz-AHI and the PSG-AHI with and without additional SpO2 measurement was rp = 0.94 and rp = 0,87, respectively. In general, the Bland-Altman plots showed good agreement between the two methods of AHI measurement, though their deviations became larger with increasing sleep-disordered breathing. Sensitivity and specificity for recordings without additional SpO2 was 85% and 88%, respectively. Adding a SpO2 sensor increased the sensitivity to 88% and the specificity to 98%.
Conclusion: The Sleepiz One + device is a valid diagnostic tool for patients with moderate to severe OSA. It can also be easily used in the home environment and is therefore beneficial for e.g. immobile and infectious patients. TRIAL REGISTRATION NUMBER AND DATE OF REGISTRATION FOR PROSPECTIVELY REGISTERED TRIALS: This study was registered on clinicaltrials.gov (NCT04670848) on 2020-12-09.
期刊介绍：
The journal Sleep and Breathing aims to reflect the state of the art in the international science and practice of sleep medicine. The journal is based on the recognition that management of sleep disorders requires a multi-disciplinary approach and diverse perspectives. The initial focus of Sleep and Breathing is on timely and original studies that collect, intervene, or otherwise inform all clinicians and scientists in medicine, dentistry and oral surgery, otolaryngology, and epidemiology on the management of the upper airway during sleep.
Furthermore, Sleep and Breathing endeavors to bring readers cutting edge information about all evolving aspects of common sleep disorders or disruptions, such as insomnia and shift work. The journal includes not only patient studies, but also studies that emphasize the principles of physiology and pathophysiology or illustrate potentially novel approaches to diagnosis and treatment. In addition, the journal features articles that describe patient-oriented and cost-benefit health outcomes research. Thus, with peer review by an international Editorial Board and prompt English-language publication, Sleep and Breathing provides rapid dissemination of clinical and clinically related scientific information. But it also does more: it is dedicated to making the most important developments in sleep disordered breathing easily accessible to clinicians who are treating sleep apnea by presenting well-chosen, well-written, and highly organized information that is useful for patient care.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
